Hemostatic Agents (To Promote Clotting)
- Aminocaproic Acid.†† Enhances clotting by slowing or stopping fibrinolysis (the
breakdown of blood clots).†
- Tranexamic Acid.† Enhances clotting by slowing or stopping fibrinolysis (the
breakdown of blood clots).
- Aprotinin.†† A naturally occurring agent isolated
from bovine lung tissue that reduces bleeding during and after
surgery.† The mechanism by which
aprotinin minimizes bleeding is thought to involve effects on platelet
function as well as on coagulation and fibrinolysis.
- Desmopressin.†† A synthetic version of a naturally
occurring hormone.† Desmopressin
causes a dose-dependent increase in plasma factor VIII, plasminogen
activator, and to a lesser degree, factor VIII-related antigen and
ristocetin cofactor activities.†
Large IV doses of desmopressin increase factor VIII activity in
healthy individuals, in patients with mild to moderate hemophilia A and B
or von Willebrands disease, and in patients with uremia.
- Topical Hemostatic Agents.† Pads, powders, pastes, sponges,
solutions, meshes and special dressings that may be used before and during
surgery to control blood loss from open wounds by promoting the clotting
of whole blood, or plasma.† In many
types of surgery, several hemostatic agents may be combined for better
hemostasis.† Thrombin is a
commercially available hemostatic agent of bovine or human origin.
- Tissue Adhesives.†† These are products used to decrease
blood loss.† Fibrin glue is a
human-derived tissue adhesive that may be used for hemostasis and sealing
of tissues.† This biological glue
can be manufactured from clotting factors taken from donor plasma
(fibrinogen and thrombin) or made intraoperatively out of fibrinogen
coming from the patientís own blood.†
Tissue adhesives may be used topically or to seal wound surfaces to
reduce postoperative bleeding, decrease or eliminate the need for sutures,
as well as in treating thermal injuries.
- Vitamin K (Phytonadione).† A synthetic product identical to
naturally occurring vitamin K.† It
is required for the production of certain blood clotting factors (factors
II, VII, IX, and X) in the liver.
antihemophilic (clotting) factors are biosynthetic forms of endogenous
(naturally occurring) human blood coagulation factors.† They are prepared using recombinant DNA
technology (genetically engineered) and produce the same biological effects as
the corresponding plasma-derived clotting products.
- Recombinant Factor VIIa.†
†Recombinant factor VIIa prevents or controls bleeding in
patients with hemophilia, thrombocytopenia, and patietns with severe
multiple factor deficiencies.
- Recombinant Factor VIII.†† Factor VIII is essential for blood
clotting and the maintenance of effective hemostasis.† Recombinant factor VIII provides a
means of temporarily replacing missing or dysfunctional factor VIII in
order to prevent or control bleeding episodes or to perform emergency or
elective surgery in patients with hemophilia A.
- Recombinant Factor IX.† This recombinant product provides a
means of temporarily replacing missing factor IX in order to prevent or
control excessive bleeding in patients with hemophilia B.